Corcept Therapeutics (CORT) Tops Q4 EPS by 3c
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $91.88 -1.47%
EPS Growth %: -96.6%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
CCEL, FEIM, PLG, More
EPS Growth %: -96.6%
Financial Fact:
Net loss and comprehensive loss: 2.59M
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of $0.18, $0.03 better than the analyst estimate of $0.15. Revenue for the quarter came in at $66.8 million versus the consensus estimate of $69.61 million.
GUIDANCE:
Corcept Therapeutics sees FY2019 revenue of $285-315 million, versus the consensus of $298.3 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
- Helen of Troy (HELE) Tops Q1 EPS by 22c, Beats on Revenue; Offers FY Guidance
- Morgan Stanley Downgrades Cosmos Pharmaceuticals Corp. (3349:JP) (CSMYF) to Equalweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
